Journal
JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS
Volume 30, Issue 2-3, Pages 102-109Publisher
MARY ANN LIEBERT, INC
DOI: 10.1089/jop.2013.0179
Keywords
-
Categories
Funding
- National Institutes of Health [EY 07065, EY 21727]
- Mayo Foundation, Rochester, MN
- Research to Prevent Blindness, New York, NY
- Lew R. Wasserman Merit Award
- Department of Ophthalmology
Ask authors/readers for more resources
Elevated intraocular pressure (IOP) is the most prevalent risk factor for glaucoma. All treatments, whether surgical or pharmaceutical, are aimed at lowering IOP. Prostaglandin analogues are a first line therapy for glaucoma due to their ability to reduce IOP, once-daily dosing, efficacy, and minimal side-effect profile. Whereas prostaglandin analogues have been known to alter aqueous humor outflow through the unconventional (uveoscleral) pathway, more recent evidence suggests their action also occurs through the conventional (trabecular) pathway. Understanding how prostaglandin analogues successfully lower IOP is important, as this information may lead to the discovery of new molecular targets for future therapeutic intervention. This review explores the current understanding of prostaglandin analogue biology as it pertains to IOP reduction and improved aqueous humor outflow facility.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available